מזומנים למניה אחת phathompharma.com (PHAT)

Phathom Pharmaceuticals maintains its leadership in treating gastrointestinal pathologies thanks to its proprietary drug Voquezna. The change in cash position per share clearly demonstrates the liquidity of the base, where the 2.27 indicator expresses the state of the metric. The company is currently scaling distribution among gastroenterologists, relying on prescription drug sales through pharmacy chains and the US health insurance system.
פילוחי מדדים מקיפים ואנליטיקה עבור phathompharma.com (PHAT)

Analyzing the current liquidity per share confirms the status of Phathom Pharmaceuticals (PHAT) as a resilient player in the non-cyclical gastroenterology segment. This indicator reflects the actual volume of free cash flow per share, where growth signals financial autonomy and stagnation indicates a risk of underinvestment in drug development, which ultimately determines the issuer's overall strength.